Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Atopic keratoconjunctivitis and atopic dermatitis.

Authors
  • Guglielmetti, Stefano
  • Dart, John Kg
  • Calder, Virginia
Type
Published Article
Journal
Current Opinion in Allergy and Clinical Immunology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Oct 01, 2010
Volume
10
Issue
5
Pages
478–485
Identifiers
DOI: 10.1097/ACI.0b013e32833e16e4
PMID: 20720488
Source
Medline
License
Unknown

Abstract

Recalcitrant AKC may be a blinding condition. Understanding the immunopathogenesis of atopic dermatitis and AKC has already influenced therapy and is essential to the development of future immunomodulatory treatments. The successful management of AKC requires the use of topical cromones, antihistamines and calcineurin inhibitors. Severely affected patients also require systemic immunosuppressive therapy. The current challenge is to find more specific topical and systemic immunomodulatory therapies with a better side-effect profile.

Report this publication

Statistics

Seen <100 times